fbpx
Ian F. Deveau - Acting Division Director at FDA/CDER. Wearing a gray shirt with a red tye. The image is a close up showing his face down to his waist. Caption reads: “But I want to emphasize that while we need to move the needle to enhance the quality of compounded drugs, there are compounding facilities making quality drugs for patients who may need them.”

FDA Finalizes Insanitary Conditions Guidance for Compounding Facilities

by | Nov 6, 2020 | All Posts, EagleTrax, FDA

The FDA has issued a statement with further emphasis on its intentions to increase enforcement against Insanitary conditions at compounding facilities. The statement comes after the FDA published its Final Guidance Document which adds recent examples from visits to compounding facilities.

According to the update published on Friday, November 6, 2020, at 10:40 EST, “These insanitary conditions include dirt, mold, insects, trash, peeling paint, unclean exhaust vents, and dirty high-efficiency particulate air (HEPA) filters, among many other examples.”

With regards to commentary received from the industry following the initial publication, FDA stated:

“Based on comments to the revised draft guidance, we also added recommendations for compounders to use risk management tools to develop appropriate controls to prevent insanitary conditions at their facilities.”

Who We Are

Eagle consultants and scientists are helping compounding facilities implement successful quality systems. Our team has over 200 years of combined experience in the FDA-regulated pharmaceutical industry and can provide guidance in establishing the systems and processes that will help facilities producing compounded medications meet and exceed regulatory expectations. Follow the link below to learn more about our consulting services.

Eagle Analytical